American biopharmaceutical company Gilead Sciences hired a former Roche executive to help it launch its hep C and hep B drugs in China, a market with big potential. Those plans now appear to include building a manufacturing facility there, its first outside of the U.S., although the company has not formally announced anything and declined to comment.
But Gilead tipped its hand this week via Twitter. A tweet to recruit workers for its China efforts included a link to this site that talked about its hepatitis and HIV treatments and mentioned the production plans.
“Today, we have a regulatory team in Beijing and a Chemical Manufacturing Outsourcing group at the Hongqiao Business Center in Shanghai. Gilead is constructing a new manufacturing site in the Hangzhou Economic Development Area. This will be the first manufacturing site constructed by Gilead outside of the U.S. and it has the potential to grow in the future,” read the info, which is in both English and Chinese.